Welcome to LookChem.com Sign In|Join Free
  • or
2-phenyl-2-(propylamino)cyclohexanone is a complex organic compound with the molecular formula C16H23NO. It features a cyclohexanone ring, which is a six-membered carbon ring with a ketone group (C=O) at the 2-position. Attached to this ring is a phenyl group (C6H5) at the 2-position and a propylamine group (C3H7NH) at the same 2-position, indicating that both substituents are directly connected to the cyclohexanone ring. 2-phenyl-2-(propylamino)cyclohexanone is known for its potential applications in the pharmaceutical industry, particularly as a precursor in the synthesis of certain drugs. It is important to note that handling and use of this chemical should be done with caution, as it may have specific safety and health considerations.

7015-53-4

7015-53-4 Suppliers

This product is a nationally controlled contraband or patented product, and the Lookchem platform doesn't provide relevant sales information.

7015-53-4 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 7015-53-4 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 7,0,1 and 5 respectively; the second part has 2 digits, 5 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 7015-53:
(6*7)+(5*0)+(4*1)+(3*5)+(2*5)+(1*3)=74
74 % 10 = 4
So 7015-53-4 is a valid CAS Registry Number.

7015-53-4Downstream Products

7015-53-4Relevant academic research and scientific papers

Improved methods for thermal rearrangement of alicyclic α-hydroxyimines to α-aminoketones: Synthesis of ketamine analogues as antisepsis candidates

Elhawi, Hagit,Eini, Hadar,Douvdevani, Amos,Byk, Gerardo

, p. 6784 - 6807 (2012/09/07)

Ketamine is an analgesic/anesthetic drug, which, in combination with other drugs, has been used as anesthetic for over 40 years. Ketamine induces its analgesic activities by blocking the N-methyl-D-aspartate (NMDA) receptor in the central nervous system (CNS). We have reported that low doses of ketamine administrated to patients before incision significantly reduced post-operative inflammation as reflected by reduced interleukin-6 (IL-6) sera-levels. Our data demonstrated in a rat model of Gram-negative bacterial-sepsis that if we inject a low dose of ketamine following bacterial inoculation we reduce mortality from approximately 75% to 25%. Similar to what we have observed in operated patients, the levels of TNF-α and IL-6 in ketamine-treated rats were significantly lower than in septic animals not treated with ketamine. On the base of these results, we have designed and synthesized series of new analogues of ketamine applying a thermal rearrangement of alicyclic α-hydroxyimines to α-aminoketones in parallel arrays. One of the analogues (compound 6e) displayed high activity in down-regulating the levels of IL-6 and TNF-α in vivo as compared to ketamine.